Cas9 Stable Cell Line - CNE1

The CNE1-Cas9 stable cell line is the preferred model for nasopharyngeal carcinoma (NPC) research. It is established by integrating the Cas9 nuclease into the human CNE1 cell line. CNE1 is a well-differentiated squamous cell carcinoma cell line derived from the nasopharynx of patients, representing an important subtype of NPC, which is more common in southern China and Southeast Asia. Constitutive expression of Cas9 in this cell line ensures that gene editing mechanisms are always at an optimal level, thus providing an efficient and reproducible system for CRISPR-mediated genome editing. By screening for stably integrated Cas9 and validating its enzymatic activity, this cell line eliminates the variability and cytotoxicity associated with traditional transient transfection methods, making it a reliable platform for functional genomics research in the context of differentiated NPC.

The main applications of the CNE1-Cas9 stable cell line are in studying the pathogenesis of NPC and identifying novel therapeutic targets. Researchers use this model for large-scale CRISPR screening to discover genes involved in virus-mediated tumorigenesis (e.g., EB virus interaction), radioresistance, and tumor invasion mechanisms. The CNE1-Cas9 cell line is particularly suitable for constructing homologous clones with specific gene knockout or knock-in, enabling scientists to study the role of single genetic markers in nasopharyngeal carcinoma progression. Furthermore, it serves as a reliable platform for evaluating the efficacy of targeted therapies and screening for small-molecule inhibitors that enhance the chemosensitivity of nasopharyngeal carcinoma cells. Its well-defined background and stable Cas9 expression make it an indispensable resource for advancing precision oncology research in head and neck cancers.